No Data
Allarity Highlights Stenoparib Progress in New Investor Presentation
Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm
Allarity Therapeutics Shares Are Trading Higher After the Company Announced That Its Active Pharmaceutical Ingredient Manufacturing Campaign for Stenoparib Is Progressing in Line With the Planned Timeline for Completion, No Later Than Q3 of 2026, at...
Allarity Therapeutics Advances Stenoparib Toward Pivotal Development With Phase 3 Manufacturing Campaign
Allarity Therapeutics Announces That the Stenoparib DRP Test Has Received a Notice of Allowance From the US Patent and Trademark Office
Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib's Potential in Colorectal Cancer as Well as New Predictive Data Linking DRP and Overall Survival in Ovarian Cancer